KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short-Term Debt issuances (2019)

Castle Biosciences (CSTL) has disclosed Short-Term Debt issuances for 1 consecutive years, with $11.7 million as the latest value for Q1 2019.

  • Quarterly Short-Term Debt issuances changed N/A to $11.7 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2019, changed N/A year-over-year, with the annual reading at $11.7 million for FY2019, N/A changed from the prior year.
  • Short-Term Debt issuances hit $11.7 million in Q1 2019 for Castle Biosciences.
  • In the past five years, Short-Term Debt issuances ranged from a high of $11.7 million in Q1 2019 to a low of $11.7 million in Q1 2019.